You are here: Industry Insights > Aytu BioScience

News List

Aytu BioScience, Neos Therapeutics Announce Merger Agreement americanpharmaceuticalreview
December 31, 2020
Aytu BioScience and Neos Therapeutics have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience firstwordpharm
December 25, 2019
The registration statement containing the joint preliminary proxy statement/prospectus is available through the SEC's website at www.sec.gov and on each company's website on the respective company's Investor section.
Aytu BioScience Announces Appointment of Two New Directors, Steven Boyd and Ketan Mehta firstwordpharma
December 04, 2018
Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced two new appointments to the Company's board of directors. Ketan Mehta, Fou
Aytu BioScience Announces Appointment of Two New Directors, Steven Boyd and Ketan Mehta firstwordpharma
December 04, 2018
Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced two new appointments to the Company's board of directors. Ketan Mehta, Fou
Aytu BioScience Announces Closing of $12,000,000 Public Offering biospace
March 07, 2018
Aytu BioScience, Inctoday announced the closing of its previously announced underwritten public offering for total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
Aytu BioScience Announces Pricing of $12,000,000 Public Offering biospace
March 05, 2018
Aytu BioScience, Inc. today announced the pricing of an underwritten public offering with expected total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.